SYRACUSE, N.Y.–(BUSINESS WIRE)– #ClinicalTrials–Central New York Biotech Accelerator (CNYBAC). -– Zetagen Therapeutics, Inc., a private, clinical stage, biopharmaceutical company focused on developing proprietary carriers delivering tumoricidal therapies for metastatic and primary breast cancer, which may minimize patient side effects with the potential to increase survival rates, announced today in 2024 they nearly doubled their worldwide IP portfolio to 64 patents, spanning across 36 countries including the